Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 2, 2022

BP Elements

  • BioPharm International's BP Elements, September 2022
  • Volume 1
  • Issue 9

Roche Launches Digital PCR System

Roche’s Digital LightCycler System is designed to aid in diagnostics for cancer, genetic disease, and infection.

Roche recently announced the launch of its first digital polymerase chain reaction (PCR) system, the Digital LightCycler System (DLS). The DLS is designed to detect disease and accurately quantify trace amounts of specific DNA and RNA targets that are not typically detectable by conventional PCR methods.

According to an Aug. 23, 2022 press release, the DLS will allow clinical research to divide DNA and RNA from a clinical sample into up to 100,000 microscopic individual reactions. This provides opportunities for high precision analysis, including identifying ultra-rare targets or accurately quantifying how much of the target DNA/RNA there is at a molecular level.

"Understanding the hidden characteristics of serious diseases is fundamental for ensuring that the most effective treatment is selected for each patient," said Thomas Schinecker, CEO, Roche Diagnostics, in the press release. “The Digital LightCycler System will support clinical researchers and laboratories in identifying rare and emerging disease mutations. This can be instrumental in early diagnosis and therapy decisions."

Source: Roche


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.